@article{1b9f403ad9384df88295402eecdb05c7,
title = "Ganglionic Acetylcholine Receptor Antibodies in Postural Tachycardia Syndrome",
abstract = "ObjectivePostural tachycardia syndrome (POTS), the most common form of dysautonomia, may be associated with autoimmunity in some cases. Autoantibodies against the ganglionic acetylcholine receptor (gAChR) have been reported in a minority of patients with POTS, but the prevalence and clinical relevance is unclear.MethodsClinical information and serum samples were systematically collected from participants with POTS and healthy control volunteers (n = 294). The level of positive gAChR antibodies was classified as very low (0.02-0.05 nmol/L), low (0.05-0.2 nmol/L), and high (>0.2 nmol/L).ResultsFifteen of 217 patients with POTS (7%) had gAChR antibodies (8 very low and 7 low). Six of the 77 healthy controls (8%) were positive (3 very low and 3 low). There were no clinical differences between seropositive and seronegative patients with POTS.ConclusionsPrevalence of gAChR antibody did not differ between POTS and healthy controls, and none had high antibody levels. Patients with POTS were not clinically different based on seropositivity. Low levels of gAChR antibodies are not clinically important in POTS.",
author = "Meredith Bryarly and Raj, {Satish R.} and Phillips, {Lauren T} and Hynan, {Linda S} and Okamoto, {Luis E.} and Arnold, {Amy C.} and Paranjape, {Sachin Y.} and Megan Vernino and Black, {Bonnie K.} and Steven Vernino",
note = "Funding Information: Funded by a grant from Dysautonomia International. This work was also supported in part by the National Center for Advancing Translational Sciences Grants UL1TR000445, UL1TR001105, and UL1RR024982. Funding Information: M. Bryarly: consultant for BioHaven and Biogen; and research support from Theravance Biopharma USA, Grifols and Dysautonomia International. S.R. Raj: consultant for Lundbeck NA Ltd., Theravance Biopharma USA, Arena Pharmaceuticals, Medscape LLC, Spire Learning, and Academy for Continuing Healthcare Learning GE Healthcare, Abbott and Allergan. L. Phillips: consultant for ACI Clinical - Neurology Endpoint Adjudication Committee; research support from NINDS, Grifols and Dysautonomia International. L.S. Hynan performed the statistical analysis and reports no disclosures relevant to the manuscript. L.E. Okamoto reports no disclosures relevant to the manuscript. A.C. Arnold: consultant for Vaccine Injury Compensation Program, Department of Health and Human Services. S.Y. Paranjape reports no disclosures relevant to the manuscript. M. Vernino: currently employed by Pfizer and reports no disclosures relevant to the manuscript. B.K. Black reports no disclosures relevant to the manuscript. S. Vernino: consultant for Catalyst, Alterity and Sage Therapeutics; and research support from BioHaven, Genentech, Grifols, Dysautonomia International, and Quest Diagnostics (through a licensing agreement). Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp . Acknowledgment Publisher Copyright: {\textcopyright} 2023 American Academy of Neurology.",
year = "2021",
month = aug,
day = "1",
doi = "10.1212/CPJ.0000000000001047",
language = "English (US)",
volume = "11",
pages = "E397--E401",
journal = "Neurology: Clinical Practice",
issn = "2163-0402",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}